People · Operator
Named in public records as an officer, director or promoter · active 2013–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Viracta Therapeutics, INC. | — | Biotechnology | Series C | $164.6M | $2.1B | 2020 |
| Akari Therapeutics Plc | — | Biotechnology | Series C | $140.5M | $34.0M | 2013 |
Gur Roshwalb at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gur Roshwalb on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick Soon-Shiong | 1 | 16 |
| Ivor Royston | 1 | 7 |
| Samir Patel | 1 | 7 |
| David Sidransky | 1 | 7 |
| Hoyoung Huh | 1 | 7 |
| JAMES HILL | 1 | 6 |
| MARK COHEN | 1 | 5 |
| Roger Pomerantz | 1 | 4 |
| James Woody | 1 | 4 |
| Yuval Cohen | 1 | 4 |
| Wendy DiCicco | 1 | 4 |
| Paul Goddard | 1 | 4 |
| Donald Williams | 1 | 4 |
| Armen Shanafelt | 1 | 3 |
| Frederick Dotzler | 1 | 3 |
| Ronald Berenson | 1 | 3 |
| Johnson Lau | 1 | 3 |
| DOV ELEFANT | 1 | 3 |
| James N. Woody | 1 | 3 |
| Barry Simon | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.